Aktienanalyse zu Heartflow Inc (HTFL)HTFLHeartflow Inc

Heartflow, Inc. is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). Its novel Heartflow Platform uses AI and advanced computational fluid dynamics to create a personalized 3D model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Heartflow RoadMap Analysis, Heartflow FFRCT Analysis, Heartflow Plaque Analysis and Heartflow PCI Navigator. Its Heartflow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. Heartflow RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review. Heartflow FFRCT Analysis calculates blood flow and pinpoints clinically significant CAD. It operates in the Healthcare sector.

HeartFlow Inc is currently a hold. The stock is trading at $48.29, which is below the recent analyst price target of $56 from Canaccord. However, the RSI is at 40.208, indicating potential weakness in momentum. The company has shown significant revenue growth, with Q2 2026 revenue at $64.1 million, a 48% year-over-year increase, and gross margins improved to 83%. The main risk is the negative net income, which was -$15.7 million in Q2 2026, indicating ongoing financial challenges.